Fragrance Composition and Sanitary or Incontinence Article

Abstract

A fragrance composition for use with a sanitary or incontinence article in the treatment of malodour caused by or associated with human body fluids, wherein said composition has an odour that is reminiscent of the odour of the article, as such, or the odour of the packaging material for said article, as such.

Claims

1. A fragrance composition adapted for use with a sanitary or incontinence article used in the treatment of malodour caused by or associated with human body fluids, wherein said fragrance composition has an odour that is reminiscent of the odour of the article, or reminiscent of the odour of a packaging material for said article.

2. The fragrance composition according to claim 1, comprising at least one fragrance ingredient selected from the group consisting of: 2,3,3-trimethyl indanone; 4-(2-methylbutan-2-yl)cyclohexan-1-one; para-tertiary butyl cyclohexyl acetate; and mixtures thereof.

3. The fragrance composition according to claim 2, comprising 2,3,3-trimethyl indanone.

4. The fragrance composition according to claim 2, wherein said at least one fragrance ingredient is present in an amount of about 20 to 100 wt % of the fragrance composition.

5. A sanitary or incontinence article comprising a fragrance composition according to claim 1.

6. The sanitary or incontinence article according to claim 5, which is a urinary incontinence treatment article.

7. A method of preventing or ameliorating malodour caused by or associated with human body fluids, said method comprising the step of providing a sanitary or incontinence article according to claim 5 with instructions to place the article on, in or about the human body proximate to a body waste discharge area.

8. A method of promoting cleanliness, hygiene and/or well-being in an incontinent population, said method comprising the step of providing an incontinence article according to claim 5 with instructions to place the article on, in or about the human body proximate to a body waste discharge area.

9. The method of claim 8, wherein the incontinent population is a female population.

10. A method of preparing a fragrance composition adapted for use with a sanitary or incontinence article in the treatment of malodour caused by or associated with human body fluids, wherein said method comprises the step f of: selecting at least one fragrance ingredient according to claim 1.

11. A sanitary or incontinence article comprising a fragrance composition according to claim 2.

12. A sanitary or incontinence article according to claim 11, wherein the fragrance composition comprises 2,3,3-trimethyl indanone.

13. A sanitary or incontinence article according to claim 11, wherein said at least one fragrance ingredient is present in an amount of about 20 to 100 wt % of the fragrance composition.

14. A method of preventing or ameliorating malodour caused by or associated with human body fluids, said method comprising the step of providing a sanitary or incontinence article according to claim 11 with instructions to place the article on, in or about the human body proximate to a body waste discharge area.

Description

EXAMPLE 1: ODOUR INTENSITY TEST

[0066] 1.5 g each of a number of fragrance ingredients and fragrance compositions (described below) having a recognisable olfactive character was assessed for intensity versus 5% benzyl acetate normalised to an intensity score of 100: [0067] PTBCHA (100%); [0068] a coconut fragrance composition (2.5% dilution); [0069] jasmacyclene (10% dilution); [0070] Safraleine™ (10% dilution); [0071] an apricot fragrance composition (10% dilution); [0072] a plum fragrance composition (5% dilution); [0073] orivone (100%); [0074] a peach fragrance composition (20% dilution); [0075] a berry fragrance composition; [0076] a lavender fragrance composition (50% dilution); and [0077] benzyl acetate (5% dilution).

[0078] Normalized odour intensity data for the fragrance compositions and fragrance ingredients are shown in FIG. 1. The results show that coconut and berry each have too low an odour intensity to be considered for non-perfumistic/perfumistic character evaluation.

EXAMPLE 2: ESTABLISHING THE ‘NON-PERFUMISTIC’ CHARACTER OF A FRAGRANCE

[0079] 20 μL of test fragrance ingredients and fragrance compositions, previously shown in accordance with Example 1 to have intensity scores of 100 or more, were applied to individual clean sanitary or incontinence articles and the articles placed into individual 500 ml wide-top lidded glass jars. The sanitary or incontinence articles were olfactively assessed by a panel of 28 volunteers. The volunteers were each asked to select the most appropriate statement from the following: [0080] a. Perfume is present and I am sure [0081] b. Perfume is present but I am less sure [0082] c. Perfume is not present but I am less sure [0083] d. Perfume is not present and I am sure

[0084] The results, shown in FIG. 2, demonstrate that less than 50% of volunteers were sure that a perfume was present when Safraleine™, orivone and PTBCHA were applied to the incontinence article. These fragrance ingredients are, therefore, considered to be ‘non-perfumistic’ within the meaning of the present invention.

EXAMPLE 3: MALODOUR CONTROL

[0085] 20 μL PTBCHA (neat, 20%, and 50% dilutions) were applied to separate incontinence articles. 50 mL of microbially contaminated human urine was then applied to each incontinence article and the articles placed into individual 500 ml wide-top lidded glass jars and incubated for 4 hours. The jars were then assessed for malodour by a trained sensory panel.

[0086] The results are shown in Table 1 and FIG. 3, which demonstrate that increasing concentrations of PTBCHA reduce perceived malodour intensity. 100% PTBCHA shows the greatest reduction in malodour even though, at this level, less than 50% of volunteers are sure a fragrance is present.

TABLE-US-00001 TABLE 1 Perceived Malodour Intensity (mean ± standard error of the Significance of Products mean Differences* 100% PTBCHA 30.0 ± 3.1 A 50% PTBCHA 35.3 ± 2.5 A 20% PTBCHA 46.2 ± 2.1 B Urine Control (4 h 59.1 ± 0.7 C degraded urine) (*The same letter means that there are no statistically significant differences between the relevant figures.)

EXAMPLE 4: MALODOUR CONTROL

[0087] 20 μL Orivone™ (neat, 20% and 50% dilutions) were applied to separate incontinence articles. 50 mL of microbially contaminated human urine was then applied to each incontinence article and the articles placed into individual 500 ml wide-top lidded glass jars and incubated for 4 hours. The jars were then assessed for malodour by a trained sensory panel.

[0088] The results are shown in Table 2 and FIG. 4, which demonstrate that increasing concentrations of Orivone™ reduce the perceived malodour intensity. 100% Orivone™ shows the greatest reduction in malodour even though, at this level, less than 50% of volunteers are sure a fragrance is present.

TABLE-US-00002 TABLE 2 Perceived Malodour Intensity (mean ± standard error of the Significance of Products mean Differences* 100% Orivone ™ 30.0 ± 2.0 A 50% Orivone ™ 37.5 ± 2.0 B 20% Orivone ™ 39.6 ± 2.2 B Urine Control (4 h 62.6 ± 0.8 C degraded urine) (*The same letter means that there are no statistically significant differences between the relevant figures.)

EXAMPLE 5: MALODOUR CONTROL

[0089] 20 μL Safraleine™ (neat and DPG dilutions) were applied to separate incontinence articles. 50 mL microbially contaminated human urine was then applied to each incontinence article and the articles placed into individual 500 ml wide-top lidded glass jars and incubated for 4 hours. The jars were then assessed for malodour by a trained sensory panel.

[0090] The results are shown in Table 3 and FIG. 5, which demonstrate that increasing concentrations of Safraleine™ reduce perceived malodour intensity. 100% Safraleine™ shows the greatest reduction in malodour even though at this level less than 50% of volunteers are sure that a fragrance is present.

TABLE-US-00003 TABLE 3 Perceived Malodour Intensity (mean ± standard error of Significance of Products the mean Differences* Hidden Malodour 59.5 ± 2.1 A Control (4 h degraded urine) 0% Safraleine ™ 60.5 ± 2.1 A (20 μl DPG + degraded urine) 10% Safraleine ™ 41.8 ± 4.3 B 50% Safraleine ™ 30.5 ± 3.8 B 75% Safraleine ™ 18.6 ± 3.8 C 100% Safraleine ™ 13.2 ± 4.4 C (*The same letter means that there are no statistically significant differences between the relevant figures.)